MindMaze Therapeutics Holding (CHIX:MMTXZ) ROCE %: -47.38% (As of Dec. 2025)


CHIX:MMTXZ MindMaze Therapeutics Holding SA CHIX:MMTXZ
15 GF Score
Price CHF0.21
! 2 Warning Signs
View Full Analysis

What is MindMaze Therapeutics Holding ROCE %?

MindMaze Therapeutics Holding CHIX:MMTXZ +4.74% 15 ROCE % is -47.38% as of Dec. 2025. GuruFocus rates CHIX:MMTXZ with a GF Score™ of 15/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. MindMaze Therapeutics Holding's annualized ROCE % for the quarter that ended in Dec. 2025 was -47.38%.

MindMaze Therapeutics Holding  (CHIX:MMTXz) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

MindMaze Therapeutics Holding ROCE % Related Terms

MindMaze Therapeutics Holding ROCE % Historical Data

* Premium members only.

The historical data trend for MindMaze Therapeutics Holding's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindMaze Therapeutics Holding ROCE % Chart

MindMaze Therapeutics Holding Annual Data
Trend Dec24 Dec25
ROCE %
-1.10 -47.38

MindMaze Therapeutics Holding Semi-Annual Data
Dec24 Dec25
ROCE % -1.10 -47.38
CHIX:MMTXZ
15GF Score
MindMaze Therapeutics Holding SA CHIX:MMTXZ
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindMaze Therapeutics Holding ROCE % Calculation

MindMaze Therapeutics Holding's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-9.64/( ( (0.093 - 0.002) + (51.53 - 10.93) )/ 2 )
=-9.64/( (0.091+40.6)/ 2 )
=-9.64/20.3455
=-47.38 %

MindMaze Therapeutics Holding's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Dec. 2024 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Dec. 2024 )(Q: Dec. 2025 )
=-9.64/( ( (0.093 - 0.002) + (51.53 - 10.93) )/ 2 )
=-9.64/( ( 0.091 + 40.6 )/ 2 )
=-9.64/20.3455
=-47.38 %

(1) Note: The EBIT data used here is one times the annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -47.38% mean?
MindMaze Therapeutics Holding (CHIX:MMTXZ) has a ROCE % of -47.38% as of Dec. 2025.
Is MindMaze Therapeutics Holding's ROCE % too high?
MindMaze Therapeutics Holding's current ROCE % is -47.38%. Overall, MindMaze Therapeutics Holding has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's ROCE % compare to VRTX and REGN?
MindMaze Therapeutics Holding's ROCE % of -47.38% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. MindMaze Therapeutics Holding's current ROCE % is -47.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (CHIX:MMTXZ) has a current ROCE % of -47.38%. The current ROCE % is -47.38%. MindMaze Therapeutics Holding's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For MindMaze Therapeutics Holding (CHIX:MMTXZ), the current ROCE % is -47.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MindMaze Therapeutics Holding Business Description

Other Exchanges RLFTY:USAMMTX:Switzerland
Address Avenue de Secheron 15, Geneva, CHE, 1202
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
15GF Score

Get the complete analysis for CHIX:MMTXZ

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF0.21
Price